Press Release
<< Back
Verastem to Present Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
The details for the poster presentations are as follows:
Title: A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies Abstract #: 296 Poster Board #: 076 Date: Thursday, November 20, 2014 Time: 9:00am GMT Location: Exhibition Hall
Title: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapy Abstract #: 302 Poster Board #: 082 Date: Thursday, November 20, 2014 Time: 9:00am GMT Location: Exhibition Hall
Title: PI3K/mTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancer Abstract #: 439 Poster Board #: 011 Date: Friday, November 21, 2014 Time: 9:00am GMT Location: Exhibition Hall
Title: The cancer stem cell inhibitors VS-6063 (defactinib) and VS-5584 exhibit synergistic anticancer activity in preclinical models of mesothelioma Abstract #: 446 Poster Board #: 018 Date: Friday, November 21, 2014 Time: 9:00am GMT Location: Exhibition Hall |
About VS-6063
VS-6063 (defactinib) is an orally available
compound designed to target cancer stem cells through the potent
inhibition of focal adhesion kinase (FAK). Cancer stem cells are an
underlying cause of tumor resistance to chemotherapy, recurrence and
ultimate disease progression. Research by
About VS-5584
VS-5584 is an orally available compound that
has demonstrated potent and highly selective activity against class 1
PI3K enzymes and dual inhibitory actions against mTORC1 and mTORC2. In
preclinical studies, VS-5584 has been shown to reduce the percentage of
cancer stem cells and induce tumor regression in chemotherapy-resistant
models.
About
Forward-looking statements:
This press release includes
forward-looking statements about the Company’s strategy, future plans
and prospects, including statements regarding the development and
activity of the Company’s product candidates. The words “anticipate,”
“appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of the Company’s product candidates and preliminary
or interim data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that data may
not be available when we expect it to be, that the Company will be
unable to successfully complete the clinical development of its product
candidates, that the development of the Company’s product candidates
will take longer or cost more than planned, and that the Company’s
product candidates will not receive regulatory approval or become
commercially successful products. Other risks and uncertainties include
those identified under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com